To survive and remain healthy is a basic human desire and right. However, this desire continues to remain a dream for one half of the world’s population today. Nearly 1/2 of the world’s population ie., over 3 billion people, live on less than $2.50 a day. And more than 1.3 billion live in extreme poverty, less than $1.25 a day. In this scenario can personalized and regenerative medicine ever rich the poor? With the current personalized medicine approach that many biotech companies are adopting and their pricing strategies the answer is obviously no. Community level genetic screening or personal genetic tests for detection of predisposition towards Diabetes, Cancer etc., still remains expensive and unreachable for the poor and inaccessible to those who are in villages.
Clinical Regenerative medicine practice has been so far been divided into–
1) Personalized Precise Therapies- mostly Point of Care Genetic screening, 3D printed organs/ implants and Cellular and Stem cell Transplants. These are offered under individual informed consent risk. These medical services are expensive and beyond the reach of the poor.
2) Products – biologicals, in vitro expanded cellular products, biosimilars, biobetters, Growth factor concentrates, implants and devices etc. These are clearly regulated by the different FDAs for mass distribution and may someday be accessible and affordable to the poor, mostly possibly to our next generation.
In DiponEd BioIntelligence, we are striving to identify and develop newer technologies that could potentially have a very wide reach to the low middle income group patients (in India and other countries) if not the poor (as defined above). We are focusing on developing technologies that help in low cost transportation and storage of cells in smaller towns. We are working on low cost PRP’s which would cost 1/10 th of current PRP kits and preparations (average 80$). Growth factor Concentrate formulations that would cost 1/10th of existing products (average 100$). Adult Regenerative Stem Cells that would cost less than 1/100th of Adult Mesenchymal Stem Cells. BMAC kits and ADSC – SVF kits at 1/100 of existing kits (average being 1000$). Radiation Hematopoetic rescues and cancer immunotherapies are successfully being developed (for no option and relapse cases) at about 1/1000 th of the current pricing.
DiponEd has already developed many platform technologies to attain these goals, for specific disease conditions. Autoimmune conditions, Infectious diseases, Cancers, Blood related disorders, Osteochondral defects, OA of the joints, AVN, Spinal cord injuries, PA, MND, cerebral palsy, muscular dystrophies etc., are already being treated, managed and cured – with unique low cost technologies that combine cellular transplants, biomaterials and immunotherapies. The company has a experienced team of software professions, physicians, transplant surgeons and scientists who lead the show. We are actively seeking new technologies and research cooperation in these area. The company is also developing new centers across India and neighboring countries, while partnering with investors, clinicians and hospital groups.